Description

Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C43H67N11O12S2—Front Neurosci. 2021 Sep 10;15:723064.|J Pharm Biomed Anal. 2022: 115156.|J Pharm Biomed Anal. 11 December 2021, 114518.-[1]Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9.|[2]Philip J Ryan, et al. Oxytocin-receptor-expressing Neurons in the Parabrachial Nucleus Regulate Fluid Intake. Nat Neurosci. 2017 Dec;20(12):1722-1733.–90779-69-4–994.19–99.55–O=C([C@H](CSSCCC(N[C@@H](C1=O)CC2=CC=C(OCC)C=C2)=O)NC([C@@H](NC(C(NC([C@](N1)([H])[C@@H](C)CC)=O)[C@H](O)C)=O)CC(N)=O)=O)N(CCC3)[C@@H]3C(N[C@@H](CCCN)C(NCC(N)=O)=O)=O–Endocrinology; Cancer–DMSO : ≥ 16.67 mg/mL|H2O : 16.67 mg/mL (ultrasonic)–Oxytocin Receptor;Vasopressin Receptor—-GPCR/G Protein–Peptides